Evidence map›Paper›PMID 28701396›Full record

ArticleJournal of virology2017

Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus.

Pey-Jium Chang, Lee-Wen Chen, Li-Yu Chen, Chien-Hui Hung, Ying-Ju Shih, Shie-Shan Wang

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Association Between Neddylation and Immune Response.Frontiers in cell and developmental biology · 2022
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Pey-Jium ChangGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan, Taiwan peyjiumc@mail.cgu.edu.tw a483662@yahoo.com.tw.
Lee-Wen ChenDepartment of Respiratory Care, Chang-Gung University of Science and Technology, Chiayi, Taiwan.
Li-Yu ChenGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan, Taiwan.
Chien-Hui HungGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan, Taiwan.
Ying-Ju ShihGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan, Taiwan.
Shie-Shan WangDepartment of Pediatric Surgery, Chang-Gung Memorial Hospital, Chiayi, Taiwan peyjiumc@mail.cgu.edu.tw a483662@yahoo.com.tw.
Chang Gung University · TWChang Gung University of Science and Technology · TWChiayi Chang Gung Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The switch of Kaposi's sarcoma-associated herpesvirus (KSHV) from latency to lytic replication is a key event for viral dissemination and pathogenesis. MLN4924, a novel neddylation inhibitor, reportedly causes the onset of KSHV reactivation but impairs later phases of the viral lytic program in infected cells. Thus far, the molecular mechanism involved in the modulation of the KSHV lytic cycle by MLN4924 is not yet fully understood. Here, we confirmed that treatment of different KSHV-infected primary effusion lymphoma (PEL) cell lines with MLN4924 substantially induces viral lytic protein expression. Due to the key role of the virally encoded ORF50 protein in the latent-to-lytic switch, we investigated its transcriptional regulation by MLN4924. We found that MLN4924 activates the ORF50 promoter (ORF50p) in KSHV-positive cells (but not in KSHV-negative cells), and the RBP-Jκ-binding elements within the promoter are critically required for MLN4924 responsiveness. In KSHV-negative cells, reactivation of the ORF50 promoter by MLN4924 requires the presence of the latency-associated nuclear antigen (LANA). Under such a condition, LANA acts as a repressor to block the ORF50p activity, whereas MLN4924 treatment relieves LANA-mediated repression. Importantly, we showed that LANA is a neddylated protein and can be deneddylated by MLN4924. On the other hand, we revealed that MLN4924 exhibits concentration-dependent biphasic effects on 12-

Indexed as

Antigens, ViralButyric AcidCell Line, TumorCell ProliferationCyclopentanesHEK293 CellsHerpesvirus 8, HumanHumansImmediate-Early ProteinsImmunoglobulin J Recombination Signal Sequence-Binding ProteinNuclear ProteinsPromoter Regions, GeneticPyrimidinesSarcoma, KaposiTetradecanoylphorbol AcetateTrans-ActivatorsAntigens, ViralButyric AcidCyclopentanesImmediate-Early ProteinsImmunoglobulin J Recombination Signal Sequence-Binding Proteinlatency-associated nuclear antigenNAE protein, humanNuclear ProteinspevonedistatPyrimidinesRBPJ protein, humanRta protein, Human herpesvirus 8Tetradecanoylphorbol AcetateTrans-ActivatorsUbiquitin-Activating EnzymesKaposi's sarcoma-associated herpesvirusKSHVLANAlytic reactivationMLN4924ORF50

Identifiers

PMID28701396
PMCPMC5599746
OpenAlexW2734540365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.